Global phenotypic screening for antimalarials.

Malaria, a devastating infectious disease caused by Plasmodium spp., leads to roughly 655,000 deaths per year, mostly of African children. To compound the problem, drug resistance has emerged to all classical antimalarials and may be emerging for artemisinin-based combination therapies. To address the need for new antimalarials with novel mechanisms, several groups carried out phenotypic screening campaigns to identify compounds inhibiting growth of the blood stages of Plasmodium falciparum. In this review, we describe the characterization of these compounds, explore currently ongoing strategies to develop lead molecules, and endorse the concept of a "malaria box" of publicly accessible active compounds.

[1]  P. Rathod,et al.  Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance , 1996, Antimicrobial agents and chemotherapy.

[2]  S. Hoffman,et al.  Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue , 2011, Proceedings of the National Academy of Sciences.

[3]  Jaijit Bhattacharya,et al.  Open source drug discovery--a new paradigm of collaborative research in tuberculosis drug development. , 2011, Tuberculosis.

[4]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[5]  M. Zappalà,et al.  Falcipain‐2 inhibitors , 2010, Medicinal research reviews.

[6]  K. Kuhen,et al.  Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials. , 2010, Bioorganic & medicinal chemistry letters.

[7]  K. Kuhen,et al.  Imidazolopiperazines: Hit to Lead Optimization of New Antimalarial Agents , 2011, Journal of medicinal chemistry.

[8]  Jeremy L. Jenkins,et al.  Clustering and Rule-Based Classifications of Chemical Structures Evaluated in the Biological Activity Space , 2007, J. Chem. Inf. Model..

[9]  G. FitzGerald.  Re-engineering drug discovery and development. , 2011, LDI issue brief.

[10]  Phenotypic Screens, Chemical Genomics, and Antimalarial Lead Discovery , 2011, PLoS pathogens.

[11]  Michael J. Keiser,et al.  The Chemical Basis of Pharmacology , 2010, Biochemistry.

[12]  P. Rathod,et al.  High-throughput Screening for Potent and Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2005, Journal of Biological Chemistry.

[13]  P. Alonso,et al.  New medicines to improve control and contribute to the eradication of malaria. , 2009, Nature reviews. Drug discovery.

[14]  B. Tekwani,et al.  Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors. , 2007, Journal of medicinal chemistry.

[15]  David M. Shackleford,et al.  Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. , 2011, Journal of medicinal chemistry.

[16]  K. Williamson,et al.  A High-Throughput Screen Targeting Malaria Transmission Stages Opens New Avenues for Drug Development , 2011, The Journal of infectious diseases.

[17]  Joanne M. Morrisey,et al.  Variation among Plasmodium falciparum Strains in Their Reliance on Mitochondrial Electron Transport Chain Function , 2011, Eukaryotic Cell.

[18]  Yingyao Zhou,et al.  Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery , 2011, Science.

[19]  Richard J. Maude,et al.  Intrahost modeling of artemisinin resistance in Plasmodium falciparum , 2010, Proceedings of the National Academy of Sciences.

[20]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[21]  José María Bueno,et al.  An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS. , 2011, ACS medicinal chemistry letters.

[22]  Jeremy N. Burrows,et al.  The state of the art in anti-malarial drug discovery and development. , 2011 .

[23]  Alfonso Mendoza-Losana,et al.  A new molecular approach for cidal vs static antimalarial determination by quantifying mRNA levels. , 2012, Molecular and biochemical parasitology.

[24]  Gregory L. Wilson,et al.  Integrating structure-based and ligand-based approaches for computational drug design. , 2011, Future medicinal chemistry.

[25]  Bruce Russell,et al.  Spiroindolones, a Potent Compound Class for the Treatment of Malaria , 2010, Science.

[26]  M. Wolff,et al.  BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY , 1996 .

[27]  E. Winzeler,et al.  Genomics and systems biology in malaria drug discovery. , 2010, Current opinion in investigational drugs.

[28]  E. Winzeler,et al.  Validation of isoleucine utilization targets in Plasmodium falciparum , 2011, Proceedings of the National Academy of Sciences.

[29]  P. Liberator,et al.  Characterization of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG): antiparasitic activity of a PKG inhibitor. , 2006, Molecular and biochemical parasitology.

[30]  ESSENTIAL EUKARYOTIC CORE , 2004, Evolution; international journal of organic evolution.

[31]  J. Gies,et al.  Drugs and their molecular targets: an updated overview , 2008, Fundamental & clinical pharmacology.

[32]  Solomon Nwaka,et al.  Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships , 2003, Nature Reviews Drug Discovery.

[33]  Tudor I. Oprea,et al.  Rapid Evaluation of Synthetic and Molecular Complexity for in Silico Chemistry , 2005, J. Chem. Inf. Model..

[34]  F. Cohen,et al.  The Impact of Whole Genome Sequence Data on Drug Discovery—A Malaria Case Study , 2001, Molecular medicine.

[35]  L. Mayr,et al.  Collaboration versus outsourcing: the need to think outside the box. , 2011, Future medicinal chemistry.

[36]  A. Thomas,et al.  Towards an In Vitro Model of Plasmodium Hypnozoites Suitable for Drug Discovery , 2011, PloS one.

[37]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[38]  Alexey Bochkarev,et al.  Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. , 2007, Molecular and biochemical parasitology.

[39]  B. Tekwani,et al.  Generation of oxamic acid libraries: antimalarials and inhibitors of Plasmodium falciparum lactate dehydrogenase. , 2007, Journal of combinatorial chemistry.

[40]  J. Mestres,et al.  Chemical probes for biological systems. , 2011, Drug discovery today.

[41]  N. White,et al.  The de novo selection of drug–resistant malaria parasites , 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[42]  Jeremy N. Burrows,et al.  Cyclopropyl Carboxamides, a Chemically Novel Class of Antimalarial Agents Identified in a Phenotypic Screen , 2011, Antimicrobial Agents and Chemotherapy.

[43]  Jordi Mestres,et al.  Anticipating drug side effects by comparative pharmacology , 2010, Expert opinion on drug metabolism & toxicology.

[44]  C. Canfield,et al.  Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. , 1995, Experimental parasitology.

[45]  Anang A Shelat,et al.  Scaffold composition and biological relevance of screening libraries. , 2007, Nature chemical biology.

[46]  Yu Wang,et al.  Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. , 2011, Molecular and biochemical parasitology.

[47]  L. Meijer,et al.  Antimalarial drug discovery: targeting protein kinases , 2007, Expert opinion on therapeutic targets.

[48]  E. Winzeler,et al.  Target identification and validation of novel antimalarials. , 2011, Future microbiology.

[49]  M. Petzold,et al.  Novel Polymorphisms in Plasmodium falciparum ABC Transporter Genes Are Associated with Major ACT Antimalarial Drug Resistance , 2011, PLoS ONE.

[50]  K. Asadullah,et al.  Crowd sourcing in drug discovery , 2011, Nature Reviews Drug Discovery.

[51]  T. Richie,et al.  Protective immunity to pre-erythrocytic stage malaria. , 2011, Trends in parasitology.

[52]  D. Fidock,et al.  Structural Elucidation of the Specificity of the Antibacterial Agent Triclosan for Malarial Enoyl Acyl Carrier Protein Reductase* , 2002, The Journal of Biological Chemistry.

[53]  P. Rosenthal.  Falcipains and other cysteine proteases of malaria parasites. , 2011, Advances in experimental medicine and biology.

[54]  W. Stein,et al.  Transporters as mediators of drug resistance in Plasmodium falciparum. , 2010, International journal for parasitology.

[55]  Joanne M. Morrisey,et al.  Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum , 2007, Nature.

[56]  David Baker,et al.  Structural genomics of pathogenic protozoa: an overview. , 2008, Methods in molecular biology.

[57]  N. Surolia,et al.  Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum , 2001, Nature Medicine.

[58]  Michael Lanzer,et al.  Drug‐resistant malaria: Molecular mechanisms and implications for public health , 2011, FEBS letters.

[59]  P. Rathod,et al.  Variations in frequencies of drug resistance in Plasmodium falciparum. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Stefan Wetzel,et al.  The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..

[61]  W. Gutteridge,et al.  Conversion of dihydroorotate to orotate in parasitic protozoa. , 1979, Biochimica et biophysica acta.

[62]  Peter G. Schultz,et al.  A Chemical Genomic Analysis of Decoquinate, a Plasmodium falciparum Cytochrome b Inhibitor , 2011, ACS chemical biology.

[63]  A. Sali,et al.  Structural genomics of protein phosphatases , 2007, Journal of Structural and Functional Genomics.

[64]  Anang A. Shelat,et al.  Chemical genetics of Plasmodium falciparum , 2010, Nature.

[65]  Joseph L. DeRisi,et al.  Chemical Rescue of Malaria Parasites Lacking an Apicoplast Defines Organelle Function in Blood-Stage Plasmodium falciparum , 2011, PLoS biology.

[66]  S. Bertini,et al.  Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. , 2010, Current medicinal chemistry.

[67]  S. Rahlfs,et al.  Molecular Genetics Evidence for the in Vivo Roles of the Two Major NADPH-dependent Disulfide Reductases in the Malaria Parasite* , 2010, The Journal of Biological Chemistry.

[68]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[69]  Trixie Wagner,et al.  Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria , 2010, Journal of medicinal chemistry.

[70]  Alexander Hillisch,et al.  Utility of protein structures in overcoming ADMET-related issues of drug-like compounds. , 2011, Drug discovery today.

[71]  Jeremy N. Burrows,et al.  P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action , 2012, PloS one.

[72]  R. Pink,et al.  Opportunities and Challenges in Antiparasitic Drug Discovery , 2005, Nature Reviews Drug Discovery.

[73]  K. Kuhen,et al.  Cell-based optimization of novel benzamides as potential antimalarial leads , 2009, Bioorganic & medicinal chemistry letters.

[74]  Araceli,et al.  Identification and Activity of a Series of Azole-based Compounds with Lactate Dehydrogenase-directed Anti-malarial Activity* , 2004, Journal of Biological Chemistry.

[75]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[76]  Aline A. Oliveira,et al.  Antimalarial Activity of Potential Inhibitors of Plasmodium falciparum Lactate Dehydrogenase Enzyme Selected by Docking Studies , 2011, PloS one.

[77]  Peter G. Schultz,et al.  In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen , 2008, Proceedings of the National Academy of Sciences.

[78]  F. Okumu,et al.  Combining indoor residual spraying and insecticide-treated nets for malaria control in Africa: a review of possible outcomes and an outline of suggestions for the future , 2011, Malaria Journal.

[79]  A. Vaughan,et al.  Type II fatty acid synthesis is essential only for malaria parasite late liver stage development , 2008, Cellular microbiology.

[80]  Ruben Abagyan,et al.  Discovery of novel inhibitors targeting enoyl-acyl carrier protein reductase in Plasmodium falciparum by structure-based virtual screening. , 2007, Biochemical and biophysical research communications.

[81]  Bruce Russell,et al.  Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription , 2011, BMC Genomics.

[82]  S. Levy,et al.  Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity , 2003, Nature Medicine.

[83]  C. Janson,et al.  1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). , 2001, Bioorganic & medicinal chemistry letters.

[84]  Joel S. Freundlich,et al.  The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. , 2008, Cell host & microbe.

[85]  James R. Brown,et al.  Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.

[86]  Shannon K. McClintock,et al.  Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations , 2010, Malaria Journal.